June 25 (Reuters) - Grace Therapeutics, Inc GRCE.O:
GRACE THERAPEUTICS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR GTX-104
GRACE THERAPEUTICS- NDA SUBMISSION INCLUDES POSITIVE DATA FROM PHASE 3 STRIVE-ON TRIAL
Source text: ID:nGNXbN5SCn
Further company coverage: GRCE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.